So I was looking back at what happened in the biotech space a few years ago when that Pfizer deal for Global Blood Therapeutics went down. GBT stock absolutely exploded on the $5 billion takeover rumors, and it pulled the whole sector up with it. That's when some of the best biotech ETFs really had their moment.

The standouts were BBP jumping nearly 17%, then SBIO, XBI, and BBC all gaining around 14% each. These funds track different angles of the biotech space - some focus on FDA-approved drugs, others on clinical trials still in progress. XBI is probably the most liquid of the bunch with solid volume, while the Virtus funds tend to be more niche plays. All of them carry high risk obviously, but that's the biotech game.

Looking back, it's a good reminder of how M&A activity can spark sector rotations. If you're hunting for exposure to best biotech ETF options, these are worth understanding - different fee structures, different holdings, different risk profiles. The key is knowing which angle you're actually betting on.